PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Mereo BioPharma Grp (MPH)

Mereo BioPharma Grp

Director/PDMR Shareholding
RNS Number : 7421Z
Mereo BioPharma Group plc
21 May 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of Director and other PDMR Dealings

 

London, May 21, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on May 20, 2019 granted incentive awards as set out below to persons discharging managerial responsibilities (PDMRs). All the awards were granted for nil consideration and shall ordinarily be forfeit (to the extent unvested) upon cessation of service.

 

Options to acquire American Depositary Shares ("ADSs") at an exercise price of $5.40 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Equity Incentive Plan (an employees' share scheme):

 

Name of PDMR

Position

Number of ADSs over which Option granted

Denise Scots-Knight

Chief Executive Officer

87,500

Alastair MacKinnon

Chief Medical Officer

27,500

Richard Jones

Chief Financial Officer

27,500

Charles Sermon

General Counsel

27,500

Wills Hughes-Wilson

Head of Patient Access and Commercial Planning

18,000

John Richard

Head of Corporate Development

27,500

 

These Options shall normally vest and become exercisable as to one quarter on the first anniversary of their grant date and, thereafter, as to the balance in equal monthly installments over the three-year period following such anniversary.

 

Awards to either acquire ADSs at an exercise price of $5.40 per ADS (Fair Market Value at grant) or, at the Company's discretion, receive a cash amount equal to the excess, if any, over the exercise price of their Fair Market Value on the exercise date:

 

Name of PDMR

Position

Number of ADSs over which Award granted

Peter Fellner

Chairman

5,500

Anders Ekblom

Director

5,500

Peter Bains

Director

5,500

Kunal Kashyap

Director

5,500

Paul Blackburn

Director

5,500

Deepa Pakianathan

Director

5,500

Michael Wyzga

Director

5,500

 

These awards shall vest in equal monthly installments over the year following their grant date.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The forms required under the EU Market Abuse Regulation follow.

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Denise Scots-Knight

 

2

Reason for the notification

 

a)

Position/status

Chief Executive Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

87,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Alastair MacKinnon

 

2

Reason for the notification

 

a)

Position/status

Chief Medical Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Richard Jones

 

2

Reason for the notification

 

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

 

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Wills Hughes-Wilson

 

2

Reason for the notification

 

a)

Position/status

Head of Patient Access and Commercial Planning

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

18,000

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

John Richard

 

2

Reason for the notification

 

a)

Position/status

Head of Corporate Development

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information: volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Peter Fellner

 

2

Reason for the notification

 

a)

Position/status

Chairman

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Anders Ekblom

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Peter Bains

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Kunal Kashyap

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Paul Blackburn

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Deepa Pakianathan

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Michael Wyzga

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZFLFLKEFBBBQ
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close